We measured total plasma amino acid concentrations before and during pancreatic stimulation with secretin (1 clinical unit/kg/h) and caerulein (50 ng/kglh) in 28 healthy volunteers, 60 patients with chronic pancreatitis (25 mild to moderate, 35 severe), and 22 patients with non-pancreatic digestive disease. In the healthy volunteers and patients with non-pancreatic digestive disease pancreatic stimulation caused a significant decrease (p<0-001) in plasma amino acid concentration, whereas in patients with chronic pancreatitis the decrease did not occur or was only slight. 
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Results
The basal plasma amino acid concentrations of the three groups of subjects did not differ significantly (Fig 1) . In healthy volunteers and in patients with non-pancreatic digestive disease pancreatic stimulation with secretin and caerulein caused a significant decrease (p<0-001) in plasma amino acid concentration: the average per cent reductions (mean (SEM)) were 16-0 (1-5), 23-8 (2 4), and 22 2 (2 3) in the former and 13-0 (1-7), 17-1 (1-3), and 20-1 (1) (2) (3) (4) (5) in the latter at 30, 45, and 60 min during pancreatic stimulation. After the infusion stopped plasma amino acids tended to return towards basal values. In patients with chronic pancreatitis pancreatic stimulation with secretin and caerulein caused no decrease or only a slight decrease in plasma amino acids (Fig 1) . The average per cent decrease (mean (SEM)) was 5 0 (1-0), 6 5 (1-0), and 6-2 (1-0) at 30, 45, and 60 min during stimulation. The differences between the chronic pancreatitis group and the two other groups were significant (Fig 1) . Table I gives the plasma amino acid concentrations (mean (SEM)) during combined stimulation with secretin and caerulein and caerulein stimulation alone in six healthy volunteers and 24 patients with chronic pancreatitis. No significant differences were observed between these two methods of stimulation. Figure 2 shows the individual values of the maximal per cent decrease in plasma amino acid concentrations during secretin and caerulein stimulation in the three groups. In almost all cases the maximal decrease occurred at 45 or 60 min of stimulation. Only in three volunteers and four chronic pancreatitis patients did it occur at 30 min. Using the 97.5 percentile, the lower normal limit was 14-4% which has been arbitrarily rounded off to 14%. Fifty two of the 60 patients with chronic pancreatitis (20 mild to moderate, 32 severe) had values below the normal limit. All patients with non-pancreatic digestive disease had values above this limit. Compared with the pancreolauryl test and faecal chymotrypsin the sensitivity of the amino acid test was significantly greater. This was especially true for patients with mild to moderate chronic pancreatitis in whom the sensitivity of the amino acid test was 80% against 41-7% and 48% for the other two tests (see Table II ). Since the sensitivity of the Paba-test (another of the tubeless pancreatic function tests in wide use) is similar to or even lower than that of the pancreolauryl test' 2 8 it is likely that the same can be stated for the Paba-test.
To assess the specificity of the amino acid test we studied a group ofpatients affected by various non-pancreatic digestive diseases, including some with intestinal malabsorption. None of these patients had abnormal values, indicating that the test is highly specific. This might be related to the fact that the amino acid test involves a direct stimulation of the pancreas, and so it is not affected by extrapancreatic factors. This would be a major advantage over the tubeless tests currently used in the clinic which have a limited specificity. 8-'3 As for the pancreatic stimulants, the results obtained in healthy volunteers and in chronic pancreatitis patients in whom the test was repeated using caerulein alone indicate that the use of secretin is not necessary, so the elimination of this peptide can further simplify the test and render it less costly. We used caerulein instead ofcholecystokinin becaue it is a synthetic preparation, free of impurities, and it is less costly and more easily obtainable (at least in Italy) than cholecystokinin. The dose we used is probably near maximal'4; however, further studies are now in progress to establish the optimal dose of this peptide. 
